Satellos Bioscience Inc. announce that its board of directors (the "Board") has appointed Philip Lambert, Ph.D., as Chief Technology Officer ("CTO") of the Company, effective September 27, 2022. Dr. Lambert brings more than two decades of experience in pharmaceutical research and development to Satellos. He is a well published researcher, a serial entrepreneur, and a leader who has held senior positions in academia, biotechnology, non-profit, large pharmaceutical, and contract research organizations.

Dr. Lambert is an experienced drug finder who has provided the necessary preclinical data to support the entrance of more than twenty small and large molecule therapeutics into clinical trials for multiple diseases. He was a member of the management team that conducted the due diligence and sale of Sirtris Pharmaceuticals to GlaxoSmithKline for USD 720,000,000. He also cofounded, effectively grew, and sold VivoPath, a contract research organization, to Charles River Laboratories.

Dr. Lambert received his Ph.D. in neuroendocrinology from Imperial College London and was a faculty member in the Department of Psychiatry at Emory University School of Medicine.